Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
64 participants
INTERVENTIONAL
2006-01-31
2009-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT00461344
Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer
NCT00189670
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
NCT00140075
Docetaxel in Node Positive Adjuvant Breast Cancer
NCT00688740
A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine
NCT00246090
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Docetaxel + placebo vandetanib
Docetaxel
intravenous infusion
2
Vandetanib + Docetaxel
Vandetanib (ZD6474)
once daily oral dose
Docetaxel
intravenous infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vandetanib (ZD6474)
once daily oral dose
Docetaxel
intravenous infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects with a measurable lesion or bone lesions
Exclusion Criteria
* Significant cardiac events, arrhythmias or other cardiac conditions
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genzyme, a Sanofi Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Sciences & Operations
Role: STUDY_DIRECTOR
Sanofi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Budapest, , Hungary
Research Site
Pécs, , Hungary
Research SIte
Bloemfontein, , South Africa
Research Site
Cape Town, , South Africa
Research Site
Observatory, , South Africa
Research Site
Barakaldo, , Spain
Research SIte
Lleida, , Spain
Research Site
Zaragoza, , Spain
Research Site
Umeå, , Sweden
Research Site
Uppsala, , Sweden
Research Site
Västerås, , Sweden
Research Site
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2005-003592-20
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
D4200C00046
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.